Literature DB >> 6258274

Cytomegalovirus as a risk factor in renal transplantation.

D S Fryd, P K Peterson, R M Ferguson, R L Simmons, H H Balfour, J S Najarian.   

Abstract

A prospective study of 276 patients that were greater than 12 years old and received transplants between October 1, 1977 and September 30, 1979 has been undertaken. Any patient with clinical findings compatible with overt cytomegalovirus (CMV) disease was placed on a "CMV disease diagnostic protocol." All diagnosed cases of CMV occurring before November 15, 1979 have been analyzed. Eighty patients (29%) had overt CMV disease. Seventy-two (90%) of them contracted CMV within the first 3 months post-transplant. The incidence of overt CMV varied with donor type. Eight percent (4 of 49), 17% (8 of 48), 20% (5 of 25), 40% (46 of 115) and 43% (15 of 35) of HLA-identical (ID) siblings, non-ID siblings, child donor, cadaveric donor, and parental donor, respectively, contracted CMV disease. Overt clinical CMV disease influenced the graft function and patient survival rates significantly (P < 0.01). Several risk factors have been considered as possible indicators of CMV disease. These include age, sex, diabetic status, time of onset of CMV, donor and recipient CMV complement-fixing (CF) and indirect fluorescence (IF) titers. The same variables were analyzed to determine whether they might also predict the severity of the disease. Donor CF is the single most important risk factor. Recipient serology alone was not found to be a significant risk factor but 15 of 27 (56%) persons who had a negative titer and received a kidney from a donor with a positive CF titer contracted overt CMV. Nine of those 15 (60%) had moderate, severe, or lethal illness.

Entities:  

Mesh:

Year:  1980        PMID: 6258274     DOI: 10.1097/00007890-198012000-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts.

Authors:  T C Wu; R H Hruban; R F Ambinder; M Pizzorno; D E Cameron; W A Baumgartner; B A Reitz; G S Hayward; G M Hutchins
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

Review 2.  Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation.

Authors:  M T LaRocco; S J Burgert
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients.

Authors:  W F Schlech; N Meagher; A D Cohen; P Belitsky; A Macdonald; J C Leblanc
Journal:  Can J Infect Dis       Date:  1993-03

4.  A prospective study of cytomegalovirus and herpes simplex virus disease in renal transplant recipients.

Authors:  D P Walker; M Longson; N P Mallick; R W Johnson
Journal:  J Clin Pathol       Date:  1982-11       Impact factor: 3.411

5.  Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients.

Authors:  M L Jordan; R L Hrebinko; J S Dummer; D P Hickey; R Shapiro; C A Vivas; R L Simmons; T E Starzl; T R Hakala
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

6.  Cytomegalovirus infection as a complication of OKT3 therapy in kidney transplant recipients.

Authors:  P J Conlon; M Carmody; J Donohoe; S Spencer; E Smyth; J J Walshe
Journal:  Ir J Med Sci       Date:  1992-11       Impact factor: 1.568

7.  Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis.

Authors:  R Mañez; K St George; P Linden; M Martin; S Kusne; P Grossi; M Ho; C Rinaldo
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

8.  Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells.

Authors:  W J Waldman; W H Roberts; D H Davis; M V Williams; D D Sedmak; R E Stephens
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

Review 9.  Prevention of cytomegalovirus infection in the pediatric renal transplant recipient.

Authors:  P L Hibberd; R H Rubin
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

10.  Prospective cytomegalovirus surveillance in paediatric renal transplant patients.

Authors:  S Iragorri; D Pillay; M Scrine; R S Trompeter; L Rees; P D Griffiths
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.